COVID-19: Preventive Measures in Multiple Sclerosis Patients and Others on Immuno-Modulators – Neurology Times

As the global COVID-19 pandemic continues to roll on, withover 1700 confirmed cases of the novel coronavirus in the US and over 135,000 cases globally, risk of contraction has become especially relevant within the neuroimmunology community.

As many patients with multiple sclerosis, myasthenia gravis, and other neuroimmune disorders receive disease-modifying therapies (DMTs) that act on the immune system, they may face an increased risk of being infected with the virus and developing more severe symptoms.

Click here to read full article


Leave a Reply

Your email address will not be published. Required fields are marked *

Font Resize